Colon cancer screening pill developer Check-Cap sets IPO terms
This article was originally published in Clinica
Check-Cap has become the latest firm to target an initial public offering: it plans to sell 1.2 million shares at $10-12 each, giving it around $13m at the midpoint. If successful, it will trade on the Nasdaq under the ticker symbol CHEK.
You may also be interested in...
Robotic pill technology, which is already being used for diagnostic purposes, will likely be embraced for the oral delivery of biologic drugs as well. Biologic therapies currently require injections in most cases, but some are exploring specialized robotic pills as a pain-free approach that could increase convenience and compliance, and thus efficacy, of medicines. Several established companies and research centers are working on both diagnostic and biologic therapeutic applications of pill-based technologies.
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.